SARS-Cov-2疫苗接种在贝尔麻痹中的研究进展
Research Advances in SARS-Cov-2 Vaccination of Bell’s Palsy
摘要: SARS-Cov-2病毒是一种传染性强的RNA病毒，自2019年底疫情爆发以来，因其传播快、潜伏期长、病死率高等特点，全球均大力投入疫苗研发并积极推动大规模疫苗接种计划。疫苗接种作为一种重要的传染病预防措施，能够建立庞大的群体免疫规模。但随着各种类型疫苗的上市它的安全性问题仍存在各种争议，疫苗的潜在副作用问题很值得我们关注。有研究表明疫苗接种与贝尔麻痹相关，本文就疫苗接种与贝尔麻痹之间潜在的不良联系展开论述。
Abstract: SARS-Cov-2 is a highly contagious RNA virus. Since the outbreak of the epidemic at the end of 2019, due to its rapid transmission, long incubation period and high case fatality rate, SARS-Cov-2 virus has been vigorously invested in vaccine research and actively promoted large-scale vaccination programs worldwide. Vaccination, as an important infectious disease prevention measure, can es-tablish a huge scale of herd immunity. However, there are still various controversies about the safety of various types of vaccines as they are marketed, and the potential side effects of vaccines deserve our attention. Studies have shown that vaccination is associated with Bell’s palsy, and this paper discusses the potential adverse link between vaccination and Bell’s palsy.
文章引用：余怡, 杜梅, 曾浪, 骆文龙. SARS-Cov-2疫苗接种在贝尔麻痹中的研究进展[J]. 临床医学进展, 2023, 13(4): 5965-5971. https://doi.org/10.12677/ACM.2023.134843

参考文献

[1] Berg, T. and Jonsson, L. (2013) Peripheral Neuropathies: Corticosteroids and Antivirals in Bell Palsy. Nature Reviews Neurology, 9, 128-129. [Google Scholar] [CrossRef] [PubMed]
[2] Tiemstra, J.D. and Khatkhate, N. (2007) Bell’s Palsy: Diagnosis and Management. American Family Physician, 76, 997-1002.
[3] Gilden, D.H. (2006) Bell’s Palsy. Current Therapy in Neurologic Disease, 85, 207-208. [Google Scholar] [CrossRef] 
[4] Morris, A.M., Deeks, S.L., Hill, M.D., et al. (2002) Annualized Incidence and Spectrum of Illness from an Outbreak Investigation of Bell’s Palsy. Neuroepidemiology, 21, 255-261. [Google Scholar] [CrossRef] [PubMed]
[5] Zhang, W., Xu, L., Luo, T., et al. (2020) The Etiology of Bell’s Palsy: A Review. Journal of Neurology, 267, 1896-1905. [Google Scholar] [CrossRef] [PubMed]
[6] Mutsch, M., Zhou, W., Rhodes, P., et al. (2004) Use of the Inac-tivated Intranasal Influenza Vaccine and the Risk of Bell’s Palsy in Switzerland. New England Journal of Medicine, 350, 896-903. [Google Scholar] [CrossRef] 
[7] Stratton, K., Ford, A., Rusch, E., et al. (2012) Adverse Ef-fects of Vaccines: Evidence and Causality. National Academies Press, Washington DC.
[8] Zhou, W., Pool, V., Deste-fano, F., et al. (2010) A Potential Signal of Bell’s Palsy after Parenteral Inactivated Influenza Vaccines: Reports to the Vaccine Adverse Event Reporting System (VAERS)—United States, 1991-2001. Pharmacoepidemiology & Drug Safety, 13, 505-510. [Google Scholar] [CrossRef] [PubMed]
[9] Cirillo, N. and Doan, R. (2022) The Association between COVID-19 Vaccination and Bell’s Palsy. The Lancet Infectious Diseases, 22, 5-6. [Google Scholar] [CrossRef] 
[10] Castillo, R.A. and Castrillo, J. (2022) Neurological Manifes-tations Associated with COVID-19 Vaccine. Neurologia.
[11] Gupta, S. and Jawanda, M. (2022) Surge of Bell’s Palsy in the Era of COVID-19: Systematic Review. European Journal of Neurology, 29, 2526-2543. [Google Scholar] [CrossRef] [PubMed]
[12] Chen, Y., Liu, Q. and Guo, D. (2020) Emerging Coronaviruses: Genome Structure, Replication, and Pathogenesis. Journal of Medical Virology, 92, 418-423. [Google Scholar] [CrossRef] [PubMed]
[13] Dong, Y., Dai, T., Wei, Y., et al. (2020) A Systematic Review of SARS-CoV-2 Vaccine Candidates. Transduction and Targeted Therapy, 5, 237. [Google Scholar] [CrossRef] [PubMed]
[14] Cantoni, D. and Grove, J. (2023) Low Hanging Fruit for Com-batting SARS-CoV-2? EMBO Reports, 24, e56979. [Google Scholar] [CrossRef] [PubMed]
[15] Gao, Q., Bao, L., Mao, H., et al. (2020) Development of an Inacti-vated Vaccine Candidate for SARS-CoV-2. Science, 369, 77-81. [Google Scholar] [CrossRef] [PubMed]
[16] Khare, S., Niharika, S.A., et al. (2023) SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders. Applied Biochemistry and Bio-technology, 195, 1541-1573. [Google Scholar] [CrossRef] [PubMed]
[17] Khoshnood, S., Arshadi, M., Akrami, S., et al. (2022) An Over-view on Inactivated and Live-Attenuated SARS-CoV-2 Vaccines. Journal of Clinical Laboratory Analysis, 36, e24418. [Google Scholar] [CrossRef] [PubMed]
[18] Krammer, F. (2020) SARS-CoV-2 Vaccines in Development. Nature, 586, 516-527. [Google Scholar] [CrossRef] [PubMed]
[19] Delrue, I., et al. (2012) Inactivated Virus Vaccines from Chemis-try to Prophylaxis: Merits, Risks and Challenges. Expert Review of Vaccines, 11, 695-719. [Google Scholar] [CrossRef] [PubMed]
[20] 邓涛, 年悬悬, 张家友, 等. 新型冠状病毒灭活疫苗研发及应用[J]. 中国生物制品学杂志, 2021, 34(7): 761-769.
[21] Adesokan, A., Obeid, M. and Lawal, A.F. (2022) SARS-CoV-2: Vac-cinology and Emerging Therapeutics; Challenges and Future Developments. Therapeutic Delivery, 13, 187-203. [Google Scholar] [CrossRef] [PubMed]
[22] Sakurai, F., Tachibana, M. and Mizuguchi, H. (2022) Adenovirus Vector-Based Vaccine for Infectious Diseases. Drug Metabolism and Pharmacokinetics, 42, Article ID: 100432. [Google Scholar] [CrossRef] [PubMed]
[23] 崔晓峰, 孙志华, 刘俊, 等. 腺病毒载体疫苗研究进展[J]. 中国病毒病杂志, 2022, 12(6): 468-473.
[24] Logunov, D.Y., Dolzhikova, I.V., Zubkova, O.V., et al. (2021) Safety and Immunogenicity of an rAd26 and rAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine in Two Formula-tions: Two Open, Non-Randomised Phase 1/2 Studies from Russia. The Lancet, 396, 887-897.
[25] 张旋旋, 佘广彪, 刘晓雅, 等. 新冠病毒蛋白亚单位疫苗研究进展[J]. 中国医药导刊, 2022, 24(5): 434-438.
[26] Nielsen, K.H. (2014) Protein Expression-Yeast. Methods in Enzymology, 536, 133-147. [Google Scholar] [CrossRef] 
[27] Merlin, M., Gecchele, E., Capalid, S., et al. (2014) Comparative Evaluation of Recombinant Protein Production in Different Biofactories: The Green Perspective. BioMed Research International, 2014, Article ID: 136419. [Google Scholar] [CrossRef] [PubMed]
[28] Pollet, J., Chen, W.H. and Strych, U. (2021) Recombinant Protein Vac-cines, a Proven Approach against Coronavirus Pandemics. Advanced Drug Delivery Reviews, 170, 71-82. [Google Scholar] [CrossRef] [PubMed]
[29] Zhang, N.N., Li, X.F., Deng, Y.Q., et al. (2020) A Thermostable mRNA Vaccine against COVID-19. Cell, 182, 1271-1283. [Google Scholar] [CrossRef] [PubMed]
[30] Chaudhary, N., Weissman, D. and Whitehead, K. (2021) mRNA Vaccines for Infectious Diseases: Principles, Delivery and Clinical Translation. Nature Reviews Drug Discovery, 20, 817-838. [Google Scholar] [CrossRef] [PubMed]
[31] Vitiello, A. and Ferrara, F. (2021) Brief Review of the mRNA Vaccines COVID-19. Inflammopharmacology, 29, 645-649. [Google Scholar] [CrossRef] [PubMed]
[32] Locht, C. (2020) Vaccines against COVID-19. Anaesthesia Critical Care & Pain Medicine, 39, 703-705. [Google Scholar] [CrossRef] [PubMed]
[33] Principi, N. and Esposito, S. (2020) Do Vaccines Have a Role as a Cause of Autoimmune Neurological Syndromes? Frontiers in Public Health, 8, Article No. 361. [Google Scholar] [CrossRef] [PubMed]
[34] Wan, E.Y.F., Chui, C.S.L., Lai, F., et al. (2022) Bell’s Palsy Fol-lowing Vaccination with mRNA (BNT162b2) and Inactivated (CoronaVac) SARS-CoV-2 Vaccines: A Case Series and Nested Case-Control Study. The Lancet Infectious Diseases, 22, 64-72. [Google Scholar] [CrossRef] 
[35] Wong, C., Lau, K., Xiong, X., et al. (2022) Adverse Events of Special Interest and Mortality Following Vaccination with mRNA (BNT162b2) and Inactivated (CoronaVac) SARS-CoV-2 Vaccines in Hong Kong: A Retrospective Study. PLOS Medicine, 19, e1004018. [Google Scholar] [CrossRef] [PubMed]
[36] Patone, M., Handunnetthi, L., Saatci, D., et al. (2021) Neuro-logical Complications after First Dose of COVID-19 Vaccines and SARS-CoV-2 Infection. Nature Medicine, 27, 2144-2153. [Google Scholar] [CrossRef] [PubMed]
[37] Khurshid, M., Ansari, I., Ahmad, H., et al. (2022) Development of Facial Palsy Following COVID-19 Vaccination: A Systematic Review. Annals of Medicine and Surgery (London), 82, Article ID: 104758. [Google Scholar] [CrossRef] [PubMed]
[38] Goepfert, P.A., Fu, B., Chabanon, A.L., et al. (2021) Safety and Immunogenicity of SARS-CoV-2 Recombinant Protein Vaccine Formulations in Healthy Adults: Interim Results of a Randomised, Placebo-Controlled, Phase 1-2, Dose-Ranging Study. The Lancet Infectious Diseases, 21, 1257-1270. [Google Scholar] [CrossRef] 
[39] Heath, P.T., Galiza, E.P., Baxter, D.N., et al. (2021) Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. The New England Journal of Medicine, 385, 1172-1183. [Google Scholar] [CrossRef] 
[40] Kaabi, N.A., Yang, Y.K., Zhang, J., et al. (2022) Immunogenicity and Safety of NVSI-06-07 as a Heterologous Booster after Priming with BBIBP-CorV: A Phase 2 Trial. Signal Trans-duction and Targeted Therapy, 7, 172. [Google Scholar] [CrossRef] [PubMed]
[41] Hwang, I., Calvit, T.B., Cash, B.D., et al. (2004) Bell’s Palsy: A Rare Complication of Interferon Therapy for Hepatitis C. Digestive Diseases & Sciences, 97, S207-S208. [Google Scholar] [CrossRef] 
[42] Ozonoff, A., Nanishi, E. and Levy, O. (2021) Bell’s Palsy and SARS-CoV-2 Vaccines. The Lancet Infectious Diseases, 21, 450-452. [Google Scholar] [CrossRef] 
[43] Cirillo, N. and Doan, R. (2021) Bell’s Palsy and SARS-CoV-2 Vaccines—An Unfolding Story. The Lancet Infectious Diseases, 21, 1210-1211. [Google Scholar] [CrossRef] 
[44] Ozonoff, A., Nanishi, E. and Levy, O. (2021) Bell’s Palsy and SARS-CoV-2 Vaccines—An Unfolding Story—Authors’ Reply. The Lancet Infectious Diseases, 21, 1211-1212. [Google Scholar] [CrossRef] 
[45] Wan, E., Chui, C., Mok, A., et al. (2022) mRNA (BNT162b2) and Inactivated (CoronaVac) COVID-19 Vaccination and Risk of Adverse Events and Acute Diabetic Complications in Patients with Type 2 Diabetes Mellitus: A Population-Based Study. Drug Safety, 45, 1477-1490. [Google Scholar] [CrossRef] [PubMed]
[46] Matveeva, O., Nechipurenko, Y., Lagutkin, D., et al. (2022) SARS-CoV-2 Infection of Phagocytic Immune Cells and COVID-19 Pathology: Antibody-Dependent as Well as Inde-pendent Cell Entry. Frontiers in Immunology, 13, Article ID: 1050478. [Google Scholar] [CrossRef] [PubMed]

为你推荐